Belite Bio announced positive topline results from the phase 3 DRAGON trial of Tinlarebant in patients with Stargardt disease.
Tinlarebant (LBS-008) is an oral therapy designed to reduce the accumulation of cytoxic bisretinoids, toxins that cause retinal disease in Stargardt disease type 1. The drug has obtained breakthrough therapy, fast track and rare pediatric disease designations from the FDA, according to the release.
Belite Bio chief medical officer Hendrik Scholl, MD, told Healio that Tinlarebant has the potential to offer patients a treatment that can slow the progression of Stargardt